What is the latest NEPHROPLUS stock price?
The latest stored price for NEPHROPLUS is Rs 743.35 as of 2026-09-18.
gimli
NEPHROPLUS stock AI analysis
NEPHROPLUS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
NEPHROCARE HEALTH SERV L is a small-cap stock in Healthcare. This Gimli page shows the latest available NEPHROPLUS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹743.35
1W return
-0.52%
1M return
+6.33%
3M return
+2.76%
6M return
+34.19%
1Y return
n/a
Market cap
₹7,458.83 cr
PE
97.07
PB
6.68
ROE
+9.04%
ROCE
+15.48%
RSI
59.93
Turnover
₹5.63 cr
Why it can matter in screens
- Momentum: NEPHROPLUS is above 50DMA, below 200DMA; RSI is 59.93.
- Returns: 1D +1.12%, 1W -0.52%, 1M +6.33%, 3M +2.76%, 1Y n/a.
- Trend levels: 52W high ₹781.50, 52W low ₹598.70, off high -4.88%.
- Liquidity: latest turnover is ₹5.63 cr; volume vs 20D is +0.36%.
- Valuation/profitability: PE 97.07, PB 6.68, ROE +9.04%, ROCE +15.48%.
- Growth: 3Y sales CAGR +34.06%, 3Y profit CAGR n/a.
Quick Answers
Is NEPHROPLUS above its 50DMA and 200DMA?
NEPHROPLUS is above 50DMA, below 200DMA. The latest 50DMA is 691.05 and the latest 200DMA is n/a.
What are NEPHROPLUS PE, ROE and ROCE?
NEPHROPLUS has PE 97.07, ROE +9.04%, and ROCE +15.48% in Gimli's latest available snapshot.
How has NEPHROPLUS performed recently?
NEPHROPLUS has returned +6.33% over 1 month, +2.76% over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 281.75 cr | n/a | n/a | nan |
| 2026-03-31 | 265.62 cr | 62.24 cr | 30.37 cr | 3.03 |
| 2025-12-31 | 259.73 cr | 64.18 cr | 32.24 cr | 3.43 |
| 2025-09-30 | 249.61 cr | 67.81 cr | -9.47 cr | nan |
| 2025-06-30 | n/a | n/a | 23.70 cr | nan |
| 2025-03-31 | 219.19 cr | 55.41 cr | 24.87 cr | 2.48 |
| 2024-12-31 | 197.26 cr | 49.46 cr | 20.11 cr | 2.00 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 998.85 cr | 248.38 cr | 76.84 cr | 8.48 |
| 2025-03-31 | 755.81 cr | 180.74 cr | 67.10 cr | 6.69 |
| 2024-03-31 | 539.55 cr | 107.05 cr | 35.13 cr | 3.50 |
| 2023-03-31 | 414.52 cr | 52.87 cr | -11.79 cr | -1.17 |
| 2022-03-31 | 320.46 cr | 21.43 cr | -21.98 cr | -132.53 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,470.87 cr | 123.89 cr | 79.71 cr | 1,116.49 cr |
| 2025-03-31 | 996.46 cr | 125.82 cr | 257.78 cr | 584.11 cr |
| 2024-03-31 | 806.02 cr | 61.15 cr | 267.84 cr | 413.71 cr |
| 2023-03-31 | 666.23 cr | 13.19 cr | 213.73 cr | 388.63 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 232.58 cr | 113.22 cr | n/a |
| 2025-03-31 | 135.35 cr | 34.55 cr | n/a |
| 2024-03-31 | 72.28 cr | -7.72 cr | n/a |
| 2023-03-31 | 11.27 cr | -62.47 cr | n/a |
| 2022-03-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +63.85% | +8.78% | +9.05% | +3.20% | +18.32% | +0.00% |
| 2026-03-31 | +63.85% | +9.94% | +8.65% | +3.17% | +17.56% | +0.00% |
| 2025-12-31 | +63.85% | +9.30% | +8.10% | +3.10% | +18.74% | +0.00% |
| 2025-12-16 | +63.85% | +3.59% | +8.68% | +3.44% | +23.88% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze NEPHROCARE HEALTH SERV L with valuation, momentum and industry peers
- Compare NEPHROPLUS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare NEPHROPLUS with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.